125 related articles for article (PubMed ID: 19011377)
1. Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway.
St-Germain JR; Chen J; Li Q
Epigenetics; 2008 Nov; 3(6):342-9. PubMed ID: 19011377
[TBL] [Abstract][Full Text] [Related]
2. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains.
Villagra NT; Navascues J; Casafont I; Val-Bernal JF; Lafarga M; Berciano MT
Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.
Ho CL; Huang YC; Tai CK; Liu ST; Wang JK; Wang WM; Huang SM
Int J Biochem Cell Biol; 2010 Jun; 42(6):902-10. PubMed ID: 20097304
[TBL] [Abstract][Full Text] [Related]
5. The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body.
Boisvert FM; Kruhlak MJ; Box AK; Hendzel MJ; Bazett-Jones DP
J Cell Biol; 2001 Mar; 152(5):1099-106. PubMed ID: 11238464
[TBL] [Abstract][Full Text] [Related]
6. N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.
Sharma P; Murillas R; Zhang H; Kuehn MR
J Cell Sci; 2010 Apr; 123(Pt 8):1227-34. PubMed ID: 20233849
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies.
Ehm P; Nalaskowski MM; Wundenberg T; Jücker M
Nucleus; 2015; 6(2):154-64. PubMed ID: 25723258
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-dependent distribution of the transcriptional coactivator p300 in cytoplasmic inclusion bodies.
Chen J; Halappanavar S; Th' ng JP; Li Q
Epigenetics; 2007; 2(2):92-9. PubMed ID: 17965593
[TBL] [Abstract][Full Text] [Related]
9. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
Frappier L
Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
[TBL] [Abstract][Full Text] [Related]
10. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
Jeanne M; Lallemand-Breitenbach V; Ferhi O; Koken M; Le Bras M; Duffort S; Peres L; Berthier C; Soilihi H; Raught B; de Thé H
Cancer Cell; 2010 Jul; 18(1):88-98. PubMed ID: 20609355
[TBL] [Abstract][Full Text] [Related]
11. Detection of O-propargyl-puromycin with SUMO and ubiquitin by click chemistry at PML-nuclear bodies during abortive proteasome activities.
Uozumi N; Matsumoto H; Saitoh H
Biochem Biophys Res Commun; 2016 May; 474(2):247-251. PubMed ID: 27125456
[TBL] [Abstract][Full Text] [Related]
12. Role of nuclear bodies in apoptosis signalling.
Krieghoff-Henning E; Hofmann TG
Biochim Biophys Acta; 2008 Nov; 1783(11):2185-94. PubMed ID: 18680765
[TBL] [Abstract][Full Text] [Related]
13. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease.
Zimber A; Nguyen QD; Gespach C
Cell Signal; 2004 Oct; 16(10):1085-104. PubMed ID: 15240004
[TBL] [Abstract][Full Text] [Related]
14. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.
Doucas V; Tini M; Egan DA; Evans RM
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2627-32. PubMed ID: 10077561
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
16. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Yerlikaya A; Kanbur E; Stanley BA; Tümer E
Anticancer Agents Med Chem; 2021; 21(1):20-32. PubMed ID: 32781973
[TBL] [Abstract][Full Text] [Related]
17. PML Bodies in Mitosis.
Lång A; Lång E; Bøe SO
Cells; 2019 Aug; 8(8):. PubMed ID: 31416160
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid attenuates promyelocytic leukemia protein-induced cell death in breast cancer cells by activation of the ubiquitin-proteasome pathway.
Son SH; Yu E; Ahn Y; Choi EK; Lee H; Choi J
Cancer Lett; 2007 Mar; 247(2):213-23. PubMed ID: 16740359
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
Weisshaar SR; Keusekotten K; Krause A; Horst C; Springer HM; Göttsche K; Dohmen RJ; Praefcke GJ
FEBS Lett; 2008 Sep; 582(21-22):3174-8. PubMed ID: 18708055
[TBL] [Abstract][Full Text] [Related]
20. Activity-regulated cytoskeleton-associated protein Arc/Arg3.1 binds to spectrin and associates with nuclear promyelocytic leukemia (PML) bodies.
Bloomer WA; VanDongen HM; VanDongen AM
Brain Res; 2007 Jun; 1153():20-33. PubMed ID: 17466953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
